BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders
15. Januar 2021 08:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Jan. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study
16. November 2020 08:30 ET
|
BioCorRx, Inc.
Announces Promotion of Lourdes Felix to CEO; Brady Granier to Serve as President ANAHEIM, CA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire ‒ BioCorRx Inc. (OTCQB: BICX) (the “Company”), a...
BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic
31. März 2020 08:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, March 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Announces Capital Restructuring and Provides Business Update
07. Oktober 2019 08:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Oct. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides Business Update for the Third Quarter of 2018
14. November 2018 08:00 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides Business Update for the First Quarter of 2018
21. Mai 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, May 21, 2018 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided...
BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California
10. April 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, April 10, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solution in the treatment of alcohol and opioid addition, today...
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
08. Februar 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102
26. Januar 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Enters Agreement with National Institute on Alcohol Abuse and Alcoholism
14. Dezember 2017 11:23 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today...